Quantitative Systems Pharmacology (QSP) Enables Research & Translation of AMP01, a Novel Next Generation Anti-PD1 Bispecific that Amplifies & Redirects Endogenous IL15 to PD1 High Expressing T-Cells, Maximizing Efficacy & Therapeutic Index
- AMPLIFY•RTM are novel multi-specific biologics that targets and captures endogenous ligands, increasing the concentration of the ligand and extending its half-life, and targets tissue specific antigens, thus redirecting the captured ligand to specific tissues, increasing efficacy, TI, and reducing the likelihood of ADA
- AMP01, Reverb’s lead AMPLIFY•RTM program, is designed to capture and redirect endogenous IL15 to PD1 high expressing T-cells, thus providing PD1 inhibition and targeted IL15 mediated expansion of immune cells to the tumor and tumor microenvironment
- The QSP model accelerated the design and selection of AMP01, a potentially best in class novel bispecific PD1 therapy with targeted lympho proliferative action. The model provided insights into the complexity of IL15 mediated immune cell dynamics and how AMP01 amplifies the effect of endogenous IL-15 in a regulated manner, to better understand safety and efficacy for simulated variability. Early QSP model predictions show that AMP01 has the potential to be a true next generation anti-PD1, with complete PD1 blockade and superior TI and efficacy over competitor therapies tested in silico